MA34158B1 - Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée - Google Patents

Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée

Info

Publication number
MA34158B1
MA34158B1 MA35308A MA35308A MA34158B1 MA 34158 B1 MA34158 B1 MA 34158B1 MA 35308 A MA35308 A MA 35308A MA 35308 A MA35308 A MA 35308A MA 34158 B1 MA34158 B1 MA 34158B1
Authority
MA
Morocco
Prior art keywords
dihydroimidazo
component
quinazoline
combinations
solvate
Prior art date
Application number
MA35308A
Other languages
English (en)
French (fr)
Inventor
Ningshu Liu
Andrea Haegebarth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34158(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34158B1 publication Critical patent/MA34158B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA35308A 2010-04-16 2011-04-14 Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée MA34158B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
MA34158B1 true MA34158B1 (fr) 2013-04-03

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35308A MA34158B1 (fr) 2010-04-16 2011-04-14 Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée

Country Status (24)

Country Link
US (1) US20130184270A1 (enExample)
EP (1) EP2558126A2 (enExample)
JP (1) JP5886271B2 (enExample)
KR (1) KR20130098155A (enExample)
CN (1) CN102958540B (enExample)
AU (1) AU2011240003A1 (enExample)
BR (1) BR112012026480A2 (enExample)
CA (1) CA2796253A1 (enExample)
CL (1) CL2012002887A1 (enExample)
CO (1) CO6620036A2 (enExample)
CR (1) CR20120524A (enExample)
CU (1) CU20120150A7 (enExample)
DO (1) DOP2012000269A (enExample)
EA (1) EA201201414A8 (enExample)
EC (1) ECSP12012261A (enExample)
IL (1) IL222356A0 (enExample)
MA (1) MA34158B1 (enExample)
MX (1) MX2012012064A (enExample)
PE (1) PE20130191A1 (enExample)
PH (1) PH12012502069A1 (enExample)
SG (1) SG184550A1 (enExample)
TN (1) TN2012000493A1 (enExample)
WO (1) WO2011128407A2 (enExample)
ZA (1) ZA201208616B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2017153220A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CN102131771A (zh) * 2008-04-14 2011-07-20 阿迪生物科学公司 组合物及其制备和使用方法
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
SG184550A1 (en) 2012-11-29
MX2012012064A (es) 2012-12-17
JP5886271B2 (ja) 2016-03-16
IL222356A0 (en) 2012-12-31
JP2013525293A (ja) 2013-06-20
EP2558126A2 (en) 2013-02-20
US20130184270A1 (en) 2013-07-18
DOP2012000269A (es) 2012-12-15
CO6620036A2 (es) 2013-02-15
CU20120150A7 (es) 2013-02-26
CR20120524A (es) 2013-01-09
CL2012002887A1 (es) 2013-01-18
CN102958540B (zh) 2015-09-02
EA201201414A8 (ru) 2013-12-30
AU2011240003A1 (en) 2012-11-08
WO2011128407A3 (en) 2012-02-23
ZA201208616B (en) 2015-08-26
CA2796253A1 (en) 2011-10-20
CN102958540A (zh) 2013-03-06
PE20130191A1 (es) 2013-02-21
HK1182937A1 (en) 2013-12-13
WO2011128407A9 (en) 2011-12-22
BR112012026480A2 (pt) 2016-08-16
KR20130098155A (ko) 2013-09-04
WO2011128407A2 (en) 2011-10-20
ECSP12012261A (es) 2012-11-30
TN2012000493A1 (en) 2014-04-01
EA201201414A1 (ru) 2013-04-30
PH12012502069A1 (en) 2013-02-04

Similar Documents

Publication Publication Date Title
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA44674A (fr) Inhibiteurs de bromodomaine
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
EA201201414A1 (ru) КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
JP2002520273A (ja) 抗うつ効果を有する治療薬
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA44206A (fr) Comprimé orodispersible comprenant estetrol
EA200601724A1 (ru) Новые композиции для местной доставки
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
Torki et al. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells
BRPI0716214A2 (pt) Composições farmacêuticas para o tratamento de infecções fúngicas.
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
FR3056108A1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif
WO1997035574A1 (fr) Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
EP2094265B1 (en) Pyrroloy[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques